EBS (Emergent BioSolutions Inc.) Stock Financials & Earnings | Market Cap Arena

EBS (Emergent BioSolutions Inc.) Stock Financials & Earnings | Market Cap Arena

EBSEmergent BioSolutions Inc.

Mkt Cap$446M

Healthcare·Drug Manufacturers - Specialty & Generic·🇺🇸 United States·NYSE

Revenue (TTM)$743M

Net Income (TTM)$53M

EPS (TTM)$0.93

Free Cash Flow (TTM)$157M

Gross Margin48.6%

Op. Margin16.4%

Net Margin7.1%

FCF Margin21.1%

P/S Ratio (TTM)0.6x

P/E Ratio (TTM)8.5x

YoY Rev Growth-28.8%

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$164M	-$24M	-$148M
Q2 23	$338M	$123M	-$293M
Q3 23	$271M	$92M	-$242M
Q4 23	$277M	$169M	-$44M
Q1 24	$300M	$141M	$40M
Q2 24	$255M	-$66M	-$204M
Q3 24	$294M	$164M	$65M
Q4 24	$195M	$137M	-$10M
Q1 25	$222M	$119M	$50M
Q2 25	$141M	$61M	$2M
Q3 25	$231M	$139M	$77M
Q4 25	$149M	$42M	-$6M

Valuation

Quarter	P/S	P/E
Q1 23	0.5x	—
Q2 23	0.4x	—
Q3 23	0.4x	—
Q4 23	0.4x	—
Q1 24	0.4x	—
Q2 24	0.4x	—
Q3 24	0.4x	—
Q4 24	0.4x	—
Q1 25	0.5x	—
Q2 25	0.5x	3.2x
Q3 25	0.6x	5.9x
Q4 25	0.6x	8.5x

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 23	-$184M	-$199M
Q2 23	-$114M	-$127M
Q3 23	$60M	$47M
Q4 23	$32M	$21M
Q1 24	-$63M	-$73M
Q2 24	$48M	$43M
Q3 24	$154M	$148M
Q4 24	-$80M	-$82M
Q1 25	-$11M	-$15M
Q2 25	$106M	$104M
Q3 25	-$2M	-$6M
Q4 25	$78M	$74M

Capital Expenditures

CapEx

Quarter	CapEx
Q1 23	$15M
Q2 23	$13M
Q3 23	$13M
Q4 23	$11M
Q1 24	$11M
Q2 24	$5M
Q3 24	$6M
Q4 24	$2M
Q1 25	$4M
Q2 25	$3M
Q3 25	$3M
Q4 25	$4M

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 23	-46.6%	+3.6%
Q2 23	+40.9%	+99.8%
Q3 23	+12.8%	+79.7%
Q4 23	-16.2%	-16.9%
Q1 24	+82.8%	-16.4%
Q2 24	-24.6%	-27.4%
Q3 24	+8.6%	-55.3%
Q4 24	-29.6%	-36.3%
Q1 25	-26.0%	-33.9%
Q2 25	-44.7%	-69.6%
Q3 25	-21.3%	-32.6%
Q4 25	-23.6%	-24.3%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 23	$0	0.0%
Q2 23	$0	0.0%
Q3 23	$4M	1.5%
Q4 23	$4M	1.4%
Q1 24	$6M	2.0%
Q2 24	$6M	2.2%
Q3 24	$2M	0.8%
Q4 24	$4M	2.2%
Q1 25	$2M	0.7%
Q2 25	$5M	3.3%
Q3 25	$5M	2.1%
Q4 25	$5M	3.6%

OpEx Breakdown

Quarter	R&D	SG&A
Q1 23	$41M	$96M
Q2 23	$26M	$91M
Q3 23	$15M	$80M
Q4 23	$29M	$89M
Q1 24	$15M	$85M
Q2 24	$33M	$77M
Q3 24	$14M	$76M
Q4 24	$9M	$61M
Q1 25	$15M	$53M
Q2 25	$13M	$44M
Q3 25	$14M	$39M
Q4 25	$12M	$51M

Revenue Segments

Quarter	Contract Development And Manufacturing	Contracts and Grants	Product
Q1 23	$15M	$7M	$143M
Q2 23	$29M	$7M	$302M
Q3 23	$14M	$7M	$250M
Q4 23	$20M	$7M	$249M
Q1 24	$19M	$8M	$274M
Q2 24	$65M	$7M	$183M
Q3 24	$14M	$10M	$270M
Q4 24	$7M	$5M	$182M
Q1 25	—	$13M	$209M
Q2 25	—	$11M	$130M
Q3 25	—	$9M	$222M
Q4 25	—	$5M	$144M

Revenue by Geography

Quarter

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$430M	$0	$430M
Q2 23	$89M	$0	$89M
Q3 23	$88M	$0	$88M
Q4 23	$112M	$0	$112M
Q1 24	$79M	$0	$79M
Q2 24	$70M	$0	$70M
Q3 24	$150M	$0	$150M
Q4 24	$106M	$0	$106M
Q1 25	$149M	$0	$149M
Q2 25	$271M	$0	$271M
Q3 25	$246M	$0	$246M
Q4 25	$205M	$0	$205M

Shares Outstanding

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change
Q1 23	50M	+0.6%
Q2 23	51M	+1.0%
Q3 23	52M	+2.2%
Q4 23	52M	+0.2%
Q1 24	52M	+0.6%
Q2 24	53M	+0.8%
Q3 24	56M	+5.7%
Q4 24	54M	-2.5%
Q1 25	57M	+5.7%
Q2 25	54M	-5.4%
Q3 25	57M	+4.2%
Q4 25	57M	+0.4%

Revenue Per Employee

Revenue / Employee

Year	Revenue/Employee	Employees
FY 14	$316K	1K
FY 15	$379K	1K
FY 16	$445K	1K
FY 17	$447K	1K
FY 18	$459K	2K
FY 19	$603K	2K
FY 20	$717K	2K
FY 21	$734K	2K
FY 22	$447K	3K
FY 23	$656K	2K
FY 24	$1M	900
FY 25	$4K	200K